肿瘤细胞治疗研究
英文原题：ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
这些发现支持进一步开发 NK-92/5.28.z 细胞作为现货型免疫疗法用于治疗转移性 RMS。
引言：转移性横纹肌肉瘤（RMS）是一类治疗困难的肿瘤，可逃避传统疗法和内源性抗肿瘤免疫反应，亟需新的治疗策略。将嵌合抗原受体（CAR）技术应用于自然杀伤（NK）细胞，有望开发安全、有效且价格可承受的疗法，增强癌症免疫监视。方法：本研究在体外和转移性异种移植小鼠模型中，评估临床可用的 CAR 工程化 NK 细胞系 NK-92/5.28.z 对 ErbB2 阳性 RMS 的疗效。结果：NK-92/5.28.z 细胞可在体外有效杀伤 RMS 细胞，并显著延长小鼠生存期、抑制肿瘤进展。NK-92/5.28.z 细胞能够持久存在于肿瘤部位，显示其可产生有效抗肿瘤反应，有助于克服当前实体瘤治疗障碍。讨论：这些发现支持进一步开发 NK-92/5.28.z 细胞，作为治疗转移性 RMS 的现成型免疫疗法。
INTRODUCTION: Metastatic rhabdomyosarcoma (RMS) is a challenging tumor entity that evades conventional treatments and endogenous antitumor immune responses, highlighting the need for novel therapeutic strategies. Applying chimeric antigen receptor (CAR) technology to natural killer (NK) cells may offer safe, effective, and affordable therapies that enhance cancer immune surveillance. METHODS: Here, we assess the efficacy of clinically usable CAR-engineered NK cell line NK-92/5.28.z against ErbB2-positive RMS in vitro and in a metastatic xenograft mouse model. RESULTS: Our results show that NK-92/5.28.z cells effectively kill RMS cells in vitro and significantly prolong survival and inhibit tumor progression in mice. The persistence of NK-92/5.28.z cells at tumor sites demonstrates efficient antitumor response, which could help overcome current obstacles in the treatment of solid tumors. DISCUSSION: These findings encourage further development of NK-92/5.28.z cells as off-the-shelf immunotherapy for the treatment of metastatic RMS.
MEMBER ACCOUNT
登录成功会直接打开下一页。
